Marriott International Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Marriott International Inc trades at $369 (market cap $96.76B), while Regeneron Pharmaceuticals Inc trades at $676.29 (market cap $70.47B). The key difference: Marriott International Inc is the larger of the two by market cap, and Marriott International Inc pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| MAR | REGN | |
|---|---|---|
Market Cap | $96.76B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $812.27 |
52-Week Low | $255.35 | $545.46 |
Enterprise Value | $113.71B | $64.42B |
Dividend Yield | 0.8% | 0.56% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Trailing returns across standard periods
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →